Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 688076.SS

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2023: USD 54.17 M

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. Total Non-Current Liabilities is USD 54.17 M for the year ending December 31, 2023, a 711.10% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 6.68 M, a -0.71% change year over year.
  • Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 6.73 M, a -7.25% change year over year.
  • Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 7.25 M, a -29.11% change year over year.
  • Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 10.23 M, a 356.05% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
SV Wall Street
Shanghai Stock Exchange: 688076.SS

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.

CEO Mr. Wei Ding
IPO Date May 20, 2021
Location China
Headquarters Building E
Employees 1,545
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Vaccines
Description

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers formulations, such as thymalfasin products for injection, eptifibatide injections, alogliptin benzoate tablets, and oseltamivir phosphate capsules; APIs and intermediates; and drugs for type 2 diabetes and obesity, and coronavirus. It also provides pharmaceutical research, clinical, and registration services of drugs; and undertakes CDMO/CMO projects of small molecule chemical API and intermediates. The company was founded in 2009 and is headquartered in Hangzhou, China.

Similar companies

300966.SZ

Hubei Goto Biopharm Co.,Ltd.

USD 2.12

NA

688513.SS

Chengdu Easton Biopharmaceuticals Co., Ltd.

USD 4.21

NA

300653.SZ

Yantai Zhenghai Biotechnology Co., Ltd.

USD 2.77

NA

603229.SS

Zhejiang Ausun Pharmaceutical Co., Ltd.

USD 1.17

NA

603896.SS

Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

USD 2.76

NA

StockViz Staff

February 2, 2025

Any question? Send us an email